Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

with all the bad press surrounding gleevec and tasigna lately this can only help the prospects for Ponatinib to be used in a larger population than would have otherwise been the case, especially in Japan where anything labelled Novartis is now considered "dirty". If lower dosed Ponatinib is still effective and safer than 45mg. then second if not first line use is realistic and probable. 2015 might be a good year for Ariad and us.